Shareholders Approve 50% Increase in Authorized Common Stock to 450 Million Shares

summarizeSummary

Relay Therapeutics shareholders approved an amendment to increase authorized common stock by 150 million shares, providing significant flexibility for future capital raises.

check_boxKey Events

• Authorized Shares Increased

  Shareholders approved an amendment to the Certificate of Incorporation, increasing the number of authorized common stock shares from 300,000,000 to 450,000,000. This provides an additional 150,000,000 shares available for future issuance.

• Significant Potential Dilution

  The increase in authorized shares creates substantial headroom for future equity financing. If all 150 million newly authorized shares were issued, it would represent potential dilution of approximately 87.6% based on the shares voted at the annual meeting.

• Annual Meeting Results

  The company held its Annual Meeting, where shareholders also elected two Class III directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent accounting firm for 2026.

auto_awesomeAnalysis

Relay Therapeutics shareholders have approved a significant increase in the company's authorized common stock, raising the limit from 300 million to 450 million shares. This move, which finalizes a proposal from a prior PRE 14A filing on April 16, 2026, provides the company with substantial flexibility to issue new shares for future capital raises, strategic acquisitions, or equity compensation. While this authorization does not immediately dilute existing shareholders, it creates significant headroom for potential future dilution. If all 150 million newly authorized shares were issued, it would represent a substantial increase in the share count, enabling the company to fund its pipeline development and operations, especially following recent positive clinical data and FDA Breakthrough Therapy designation.